Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Reduction in HPV Prevalence

What is the role of HPV vaccination?

Young women aged 20 to 29 years who were screened for cervical cancer saw reduction in vaccine-type (VT) human papillomavirus (HPV) within 6 years of the vaccine introduction, according to a study of 4,181 women in an integrated healthcare delivery system. The study compared HPV prevalence in 2007 and 2012-13 and evaluated predictors of VT HPV and any-HPV prevalence in 2012-13. Study findings revealed:

• 31.9% of the study group had initiated HPV vaccination.

• VT HPV prevalence decreased from 10.6% in 2007 to 6.2% in 2012-13.

• VT HPV prevalence was significantly lower among individuals who initiated vaccination than among those who were not vaccinated.

Citation: Dunne EF, Naleway A, Smith N, et al. Reduction in human papillomavirus vaccine type prevalence among young women screened for cervical cancer in an integrated US healthcare delivery system in 2007 and 2012-2013. J Infect Dis. [Published online ahead of print June 29, 2015]. doi:10.1093/infdis/jiv342.